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An extract of a filamentous fungus, MSX 63935, isolated from leaf litter collected in Nigeria, displayed promising cytotoxic activity against a human tumor panel. (12, 13) Previous research on this fungal isolate has examined a variety of biological targets, including assays for methicillin-resistant Staphylococcus aureus (MRSA), tuberculosis (TB), gene regulation, activity in the CNS, and various agricultural pests. However the only positive result was against MRSA, and no antibiotic compounds had been isolated.(14) Thus, these new cytotoxicity results spawned a bioactivity-directed fractionation study, and a series of resorcylic acid lactones (RALs; 1-6) were isolated and characterized, including a new natural product, 15-O-desmethyl-(5Z)-7-oxozeaenol (1), and a new compound, 7-epi-zeaenol (3) . In conjunction with structurally related analogues purchased from commercial sources, these compounds were evaluated against the human tumor panel, yielding preliminary structure-activity relationship data. The isolated compounds (1) (2) (3) (4) (5) (6) were examined also for antibacterial activity, as well as activity in mitochondrial transmembrane potential and NF-κB inhibition assays. The NF-κB inhibition assay revealed promising hits (compounds 1 and 5), both of which had sub-micromolar activities.
RESULTS AND DISCUSSION
Through the ongoing exploration of extracts of filamentous fungi for cytotoxicity,(1) fungus MSX 63935 showed promising activity (i.e., >96% inhibition of H460 cell growth at 20 μg/mL). The solid-phase culture was scaled up to a 2.8 L Fernbach flask, and a 1:1 CHCl 3 /MeOH extract was generated, which was defatted with a 3:3:4 CH 3 CN/MeOH/hexanes partition. The resultant organic-soluble material was a white solid, which consisted almost exclusively of compounds1-6 (see Figure S1 in the Supporting Information for an analytical HPLC of this solid). In fact, of all the anticancer leads examined from this library of filamentous fungi over the past three years, MSX 63935 was one of the most proficient producers of small molecules studied to date. This white solid was advanced directly to preparative scale RP-HPLC to isolate all six compounds in >95% purity, as measured by analytical HPLC. Compound 3 was a new compound, 1 was a new natural product, and 2, 4, 5, and 6 were known compounds. Of these, the production of 5 was quite high, in excess of 800 mg from a solid-phase culture grown in a 2.8 L Fernbach flask.
The molecular formula for the major compound (5) was C 19 H 22 O 7 , as determined via HRESIMS. The NMR data, in conjunction with the HRMS data and UV maxima (from the PDA detector of the HPLC) at 234, 274, and 314 nm, indicated 5 to be the known compound (5Z)-7-oxozeaenol (also known as LL-Z1640-2),(15, 16) Tables 1 and S1 ). The major difference between the NMR data of 1 and 5 was the absence of the methoxy signals at δ H /δ C 3.80/55.5 in 1 that were present in5. A new phenol peak was observed at δ H 10.39 in 1, further supporting the absence of a methoxy moiety in 1 relative to 5. Compound 1 has been described previously as an intermediate in the synthesis of 5;(16) however, it was ascribed the trivial name 15-O-desmethyl-(5Z)-7-oxozeaenol, since it had not been described from nature previously. The absolute configuration of 1 had been established previously by synthesis. (16) The HRESIMS data of compound 2 corresponded to a formula of C 19 13 C NMR spectra, respectively, of 3). The COSY spectrum of 3 indicated the same carbon skeleton and oxygenation pattern as 2, suggesting that 2 and 3 were diastereomers.
A recent report described a C-7 epimer (C-6′ in their numbering scheme) of aigialomycin B, which differs from 2 by the presence of an epoxide at C-11/C-12 (C-1′/C-2′ in their numbering scheme) instead of an alkene.(19) The same report described both C-7 epimers of 5,6-dihydrozeaenol. Hence, given these literature precedents and the 2D-NMR data indicating that 3and 2 shared an identical skeleton and oxygenation pattern, it was hypothesized that 3 was the C-7 epimer of 2. The reduction of the C-7 ketone of (5E)-7-oxozeaenol (4; described below) was performed using sodium borohydride. The major product of the reduction of 4 had the identical retention time and UV spectrum to those of 3. Moreover, after isolation of the major reduction product by preparative HPLC, the 1 H NMR data were identical to those of isolated 3, and thus, the configuration at C-7 for 3 was established as R. That 3 was the major product of the sodium borohydride reduction of 4 was somewhat surprising, as sodium borohydride is known to give mixtures of 1,4-and 1,2-reductions of α,β-unsaturated ketones; only a trace amount of 2 was detected by HPLC in the sodium borohydride reduction of 4. Regardless, these data supported the assignment of 3 as 7-epi-zeaenol.
Compound 4 was isolated as a white powder. HRESIMS data indicated a formula identical to 5of C 19 H 22 O 7 . NMR data established 4 as the known compound (5E)-7-oxozeaenol. (18) To the best of our knowledge, the NMR data for 4 have not been reported previously, and thus they are summarized in Table S1 . The [α] D value does not appear to have been reported either (seeExperimental Section). Moreover, since the acetonide of 4 has been reported, it was synthesized, and the 1 H NMR data were in excellent agreement with literature data. (18) Compound 6 was isolated as a white powder. The HRESIMS data indicated a formula identical to 2 and 3 of C 19 H 24 O 7 . The NMR data for 6 matched that of LL-Z1640-1. (18) The [α] D of 6 was measured as −78, which compared favorably with the literature value of −81. (18) There appears to be some confusion in the literature about the absolute configuration of 6, which was determined initially by X-ray diffraction. (17) Sugawara et al. (18) later reported position C-8 as having an R configuration, whereas the X-ray studies(17) indicated C-8 as S; the latter assignment seems to be consistent on the basis of biosynthetic comparisons to the other isolated compounds.
Compounds 1-6, along with other known RALs hypothemycin (7), zearalenone (8), α-zearalenol (9), β-zearalenol (10), α-zearalanol (11), and β-zearalanol (12) were assayed against the three cancer cell lines MCF-7, H460, and SF268. The IC 50 results for 1-12 are summarized in Table2. From these, it was clear that the enone (i.e., compounds 1, 4, 5, and 7), but not exclusively acisenone (i.e., note 4), was required for cytotoxic activity. A recent review highlights some of the biology of the resorcylic acid lactones, (20) and they are known to inhibit with nanomolar potency the ATPase activity of two critical classes of proteins: the HSP90 chaperone (21, 22 ) and a subset of 16 kinases possessing a crucial cysteine residue in their ATPase binding pocket.(23)HSP90 client proteins include several oncogenic proteins, such as Src kinase, and HSP90 inhibition results in the dissociation and degradation of these proteins. The activity of the new members of this class of polyketides, described herein, toward these targets remains to be investigated.
Compounds 1-6 were examined for activity in a series of three other assays. With respect to NF-κB inhibitory activity, compound 5 (Table 3) was the most potent, being approximately a halforder of magnitude less potent than the positive control (rocaglamide). Previously, 5 was reported as a potent inhibitor of TAK1, which is a member of the mitogen-activated kinase kinase kinase (MEKK) family that participates in proinflammatory cellular signaling pathways by activating NF-κB. (24) As with the cytotoxicity data, the enone moiety seemed to enhance potency, and in this case, the cis relationship (i.e., compounds 1 and 5) was more potent than the trans relationship (i.e., compound 4). In an assay for mitochondrial transmembrane potential (MTP), all compounds displayed IC 50 values greater than 10 μM. Since the positive control for this assay, staurosporine, had an IC 50 value in the single digit nanomolar range, 1-6 were considered inactive. Finally, compounds 1-6 were examined and found inactive againstEscherichia coli, Staphylococcus aureus, Mycobacterium smegmatis, and Bacillus subtilis; MIC values were all >500 μg/mL.
In summary, a series of six structurally related resorcylic acid lactones (1-6) were isolated from MSX 63935. Data in both the cytotoxicity assays and the NF-κB assay suggest that compound 5was the most promising. Fortuitously, this fungus was a prolific producer of 5, generating over 800 mg per solid-phase culture in a 2.8 L Fernbach flask, using standard techniques prior to any growth optimization studies. As such, studies are ongoing to probe the structure-activity relationships further by using 5 as starting materials for medicinal chemistry studies and by modifying the fermentation procedures to generate various analogues.
EXPERIMENTAL SECTION

General Experimental Procedures
Optical rotations, UV spectra, and IR spectra were obtained on a 13 C) was also used for some experiments. HRESIMS was performed on a Waters SYNAPT MS system. HPLC was carried out on Varian Prostar HPLC systems equipped with Prostar 210 pumps and a Prostar 335 photodiode array detector (PDA), with data collected and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2). For preparative HPLC, a Gemini-NX C18 (5 μm; 250 × 21.2 mm) column was used at a 21.2 mL/min flow rate, while for analytical HPLC, a Gemini-NX C18 (5 μm; 250 × 4.6 mm) column was used with a 1 mL/min flow rate (both from Phenomenex, Inc.). Reference standards of (5Z)-7-oxozeaenol (5) and zeaenol (2) were obtained from EMD Chemicals. Zearalenone (8), α-zearalenol (9), β-zearalenol (10), α-zearalanol (11), and β-zearalanol (12) were obtained from Sigma-Aldrich. Hypothemycin (7) was obtained from Enzo Life Sciences. All other reagents and solvents were obtained from Fisher Scientific and were used without further purification.
Producing Organism and Fermentation
Mycosynthetix fungal strain 63935 was isolated in 1992 by Dr. Barry Katz of MYCOsearch from leaf litter collected at the Agricultural Farms, University of Nigeria, Ede. DNA analyses were performed by MIDI Laboratories, Inc. (Newark, DE), and the D2 variable region of the large subunit (LSU) rRNA was sequenced and compared to their database; the closest match could determine only that this fungus was related to Phoma sp.; these data were deposited in Genbank (accession no. JF767207). The culture was stored on a malt extract slant and was transferred periodically. A fresh culture was grown on a similar slant, and a piece was transferred to a medium containing 2% soy peptone, 2% dextrose, and 1% yeast extract (YESD media). Following incubation (7 d) at 22 °C with agitation, the culture was used to inoculate 50 mL of a rice medium, prepared using rice to which was added a vitamin solution and twice the volume of rice with H 2 O, in a 250 mL Erlenmeyer flask. This was incubated at 22 °C until the culture showed good growth (approximately 14 d). The scale-up culture was grown in a 2.8 L Fernbach flask containing 150 g of rice and 300 mL of H 2 O and was inoculated using a seed culture grown in YESD medium. This was incubated at 22 °C for 14 d.
Extraction and Isolation
To the large-scale solid fermentation was added 500 mL of 1:1 MeOH/CHCl 3 . The mixture was shaken for 16 h, then filtered, and the solvent was evaporated (3.7 g of waxy, white solid). The extract was then partitioned between CH 3 CN/MeOH/hexanes (150/150/200 mL), the CH 3 CN/MeOH solubles were separated, and the solvent was evaporated (1.7 g of white powder, Figure S1 , Supporting Information). As such, it was dissolved in 5.5 mL of DMSO and purified via seven separate injections by preparative HPLC using a gradient that initiated with 35:65 and increased linearly to 45:55 CH 3 CN/H 2 O over 40 min. Compound 1 eluted at ∼7.6 min (5.2 mg),2 at ∼9 min (90.7 mg), 3 at ∼11.8 min (5.6 mg), and 4 at ∼14 min (73.1 mg), and 5 and 6eluted together from 16 to 20 min. The mixture of 5 and 6 was subjected to two further rounds of shave-and-recycle preparative HPLC under the same conditions to yield >95% pure 5 (885.9 mg) and 6 (80.5 mg). Acetonide of (5E)-7-Oxozeaenol (4a) To 1.54 mg of 4 were added 100 μL of 2,2-dimethoxypropane and 100 μL of acetone. A trace amount of pyridinium p-toluenesulfonate was added, and the solution was stirred for 2 h at 40 °C. 
15-O-Desmethyl-(5Z)-7-oxozeaenol (1):
Reduction of 4
(5E)-7-Oxozeaenol (4; 4.6 mg) was weighed into a 2 mL reaction vial, and 0.25 mL of both 2-propanol and THF were added. The compound dissolved after brief stirring. NaBH 4 (10.6 mg) was added with continued stirring. After 30 min, the solution had turned cloudy, and by analytical HPLC the presence of 4 was not discernible. H 2 O (0.5 mL) was added to this reaction product to dissolve all solids, and this solution was purified in a single step via preparative HPLC using the aforementioned conditions. The major peak was collected between 10 and 13 min (2.53 mg; 57% yield) and was confirmed by 1 H and 13 C NMR to be identical to isolated 3.
Cytotoxicity Assay
The cytotoxicity measurements against the MCF-7(25) human breast carcinoma (Barbara A. Karmanos Cancer Center), NCI-H460(26) human large cell lung carcinoma (HTB-177, American Type Culture Collection (ATCC)), and SF-268 (27) human astrocytoma (NCI Developmental Therapeutics Program) cell lines were performed as described previously. (13) Moreover, a second cytotoxicity assay was performed on only the isolated compounds using the HT-29(28)human colorectal adenocarcinoma (HTB-38, ATCC) and the MDA-MB-435(29) human melanoma (HTB-129, ATCC) cell lines. All cells were propagated in RPMI 1640 medium supplemented with fetal bovine serum (10%), penicillin (100 units/mL), and streptomycin (100 μg/mL). Cells were plated at either 2500 (HT-29) or 5000 (MCF-7, MDA-MB-435) cells per well in 96-well microtiter plates and incubated for 16 h in a humidified, 5% CO 2 atmosphere at 37 °C. Test substance was then added at the following final concentrations: 25, 5, 1, 0.2, and 0.04 μg/mL. After a 72 h incubation, an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay was performed using a commercially available kit according to the manufacturer's instructions (CellTiter 96 AQ ueous One Solution Cell Proliferation Assay, Promega Corp.).
Antimicrobial Assay
Antibiotic activity was examined using an agar plate diffusion assay. Overnight cultures ofEscherichia coli, Staphylococcus aureus, Mycobacterium smegmatis, and Bacillus subtilis were used to inoculate molten LB media or Middlebrook 7H9 media (Difco) with 1% glycerol, containing 1.5% agar and kept at 50 °C; these were then used to prepare assay plates. Samples (dissolved in 10 μL of MeOH) were applied to the surface of the assay dish, and positive controls were treated in a similar manner (penicillin G, novobiocin, and streptomycin; all from Sigma). The bioassay plates were incubated overnight at 37 °C. Biological activity of the standards could be detected to 1 μg/mL (except that penicillin G was active against E. coli at 100 μg/mL only), whereas the test compounds showed no activity at 500 μg/mL and were thus deemed inactive.
NF-κB p65 Assay
An ELISA-based NF-κB inhibitory assay was performed as described previously.(30) Briefly, HeLa cells (ATCC CCL-2) were treated with various concentrations of test compounds, positive control, or solvent control, and their nuclei extracted using the NE-PER kit (Pierce Biotechnology). The specific binding ability of activated p65 subunits of NF-κB in the nucleus was detected according to the manufacturer's protocol (EZ-Detect Transcription Factor Assay System ELISA kit, Pierce). Rocaglamide (Enzo Life Sciences International, Inc.) was used as a positive control (IC 50 value of 0.075 μM).
Mitochondria Transmembrane Potential (ΔΨ) Assay
The mitochondrial transmembrane potential assay kit (Cayman Chemical Company) was adapted to detect the ΔΨ using a procedure published previously. 
